Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.

@article{Durn2007PhaseIT,
  title={Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.},
  author={Ignacio Dur{\'a}n and S{\'e}bastien J. Hotte and Holger Hirte and Eric Chen and Martha Maclean and S. Turner and Lixia Duan and Gregory R. Pond and Chetan Lathia and Scott N. Walsh and Reverend John J. Wright and Janet E. Dancey and Lillian L Siu},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2007},
  volume={13 16},
  pages={
          4849-57
        }
}
PURPOSE Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their inhibitory target profile and efficacy as single agents, the combination of these drugs is of considerable interest in solid malignancies. This study aimed to determine the recommended phase II dose of this targeted combination, their toxicity profile, pharmacokinetic interaction, and preliminary clinical activities. EXPERIMENTAL… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 46 CITATIONS

Similar Papers

Loading similar papers…